Population exposure-response modeling of metformin in patients with type 2 diabetes mellitus

被引:33
|
作者
Hong, Ying [1 ]
Rohatagi, Shashank [2 ]
Habtemariam, Bahru [1 ]
Walker, Joseph R. [2 ]
Schwartz, Sherwyn L. [3 ]
Mager, Donald E. [1 ]
机构
[1] SUNY Buffalo, Sch Pharm & Pharmaceut Sci, Dept Pharmaceut Sci, Buffalo, NY 14260 USA
[2] Daiichi Sankyo Pharma Dev, Edison, NJ USA
[3] Diabetes & Glandular Dis Clin, San Antonio, TX USA
来源
JOURNAL OF CLINICAL PHARMACOLOGY | 2008年 / 48卷 / 06期
关键词
type 2 diabetes mellitus; metformin; pharmacokinetics; pharmacodynamics; mathematical modeling;
D O I
10.1177/0091270008316884
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The exposure-response properties of metformin were characterized in 12 subjects with type 2 diabetes mellitus. The time course of drug concentration and effects on fasting plasma glucose and lactic acid concentrations were used from a study in which subjects received 500 mg of metformin twice daily for 5 days followed by 850 mg twice daily for 5 days. Pharmacokinetic sampling included morning trough concentrations obtained on days 7 to 9 and rich sampling (15 time points) on day 10. Fasting plasma glucose and lactic acid concentrations were measured on days 0 to 10 and served as biomarkers of therapeutic effect and tolerability, respectively. A population pharmacokinetic/pharmacodynamic analysis was conducted using nonlinear mixed effects modeling. Metformin pharmacokinetics were described using a 1-compartment model with first-order absorption. Population mean estimates (relative standard error [RSE]) of clearance (CLIF) and volume of distribution were 79.0 L.h(-1) (6.8%) and 648 L (13.8%), respectively. Covariate analyses revealed that creatinine clearance (CLCR) significantly influenced metformin CLIF [CL/F = 79.0.(CLCR/80)(0.822)]. An indirect response model was applied to describe the antihyperglycemic effect of metformin. Population mean estimates (RSE) of baseline fasting plasma glucose and the drug concentration producing half-maximal effect were 241 mg.dL(-1) (4.6%) and 4.23 mg.L-1 (31.0%). An empirical linear model was used to describe a slight progressive increase in fasting lactic acid during metformin treatment with an estimated slope coefficient (RSE) of 0.0005 mM.mL.ng(-1) (38.1 %). Model evaluation by predictive check and non-parametric bootstrap analysis suggested that the proposed model is robust, and parameter values were estimated with good precision. Simulations suggested that the clinical utility of metformin was maintained over the dose range evaluated with respect to fasting plasma glucose and lactic acid response.
引用
收藏
页码:696 / 707
页数:12
相关论文
共 50 条
  • [41] Advantages of Extended-Release Metformin in Patients with Type 2 Diabetes Mellitus
    Jabbour, Serge
    Ziring, Barry
    POSTGRADUATE MEDICINE, 2011, 123 (01) : 15 - 23
  • [42] Metformin reduces gastric cancer risk in patients with type 2 diabetes mellitus
    Tseng, Chin-Hsiao
    AGING-US, 2016, 8 (08): : 1636 - 1649
  • [43] Metformin and risk of developing nasopharyngeal cancer in patients with type 2 diabetes mellitus
    Tseng, Chin-Hsiao
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2018, 85 : 223 - 226
  • [44] Antioxidant effects of gliclazide, glibenclamide, and metformin in patients with type 2 diabetes mellitus
    Signorini, AM
    Fondelli, C
    Renzoni, E
    Puccetti, C
    Gragnoli, G
    Giorgi, G
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2002, 63 (07): : 411 - 420
  • [45] Metabolic and haemodynamic effects of metformin in patients with type 2 diabetes mellitus and hypertension
    Uehara, MH
    Kohlmann, NEB
    Zanella, MT
    Ferreira, SRG
    DIABETES OBESITY & METABOLISM, 2001, 3 (05): : 319 - 325
  • [46] Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated
    Irons, Brian K.
    Minze, Molly G.
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2014, 7 : 15 - 24
  • [47] The effect of metformin on the survival of colorectal cancer patients with type 2 diabetes mellitus
    Zeinab Tarhini
    Kamelia Manceur
    Julien Magne
    Muriel Mathonnet
    Jeremy Jost
    Niki Christou
    Scientific Reports, 12
  • [48] Tolerability of pioglitazone compared to metformin in patients with Type 2 diabetes mellitus.
    Herz, M
    Tan, MH
    Pavo, I
    Melnichenko, GA
    Shoustov, SB
    Gyimesi, A
    Varkonyi, T
    Johns, D
    Schluchter, BJ
    Widel, M
    DIABETOLOGIA, 2002, 45 : A251 - A252
  • [49] Metformin regulates glycemic homeostasis in patients with type 2 diabetes mellitus as an NO donor
    Kuznetsov, I. S.
    Serezhenkov, V. A.
    Romantsova, T. I.
    Vanin, A. F.
    DIABETES MELLITUS, 2013, 16 (03): : 41 - 45
  • [50] Therapeutic Applications of Type 2 Diabetes Mellitus Drug Metformin in Patients with Osteoarthritis
    Song, Parkyong
    Hwang, Ji Sun
    Park, Hyean Cheal
    Kim, Keun Ki
    Son, Hong-Joo
    Kim, Yu-Jin
    Lee, Kwang Min
    PHARMACEUTICALS, 2021, 14 (02) : 1 - 14